falsefalse

Post-Conference Perspectives: Updates in Colorectal Cancer: Highlights from ASCO GI 2023 and Beyond - Episode 2

Clinical Trial Review: MOUNTAINEER

An expert in gastrointestinal cancers reviews outcomes from the MOUNTAINEER clinical trial, focusing on concordance analysis data for HER2 testing as well as the efficacy of tucatinib and trastuzumab.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Introduction to Biomarker Testing in Metastatic Colorectal Cancer
    Now Viewing
    EP. 2: Clinical Trial Review: MOUNTAINEER
    EP. 3: MOUNTAINEER-03 Clinical Trial Study Design and Implications
    EP. 4: Emerging Treatment Options for Patients with HER2+ Metastatic Colorectal Cancer
    EP. 5: The Future of the Metastatic Colorectal Cancer Treatment Landscape

    Related Content:

    Post-Conference Perspectives: Updates in Colorectal Cancer: Highlights from ASCO GI 2023 and BeyondOncLive News Network®
    Novel Treatment Approaches Under Investigation in ROS1+ NSCLC
    Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC
    Pooled Data for Taletrectinib in ROS1+ NSCLC
    x